Only 4 percent of sexually active gay and bisexual men in the United States are using PrEP, according to a recently published study, showing that more must be done to reach everyone who could benefit from it.

The U.S. Food and Drug Administration has approved two new HIV treatment medications containing doravirine, a next-generation non-nucleoside reverse transcriptase inhibitor.

The latest San Francisco HIV epidemiology report shows that while the number of new infections continues to decline, African-Americans and homeless people have persistently higher infection rates and poorer outcomes.

The proportion of people with HIV who achieve viral suppression has risen dramatically across the United States over the past two decades, but young black men are not seeing the same gains, according to a new study.

Government policies can work against achieving an end to HIV by limiting access to prevention and treatment for the most heavily affected groups, according to research presented at the 22nd International AIDS Conference last week in Amsterdam.

Activists kicked off this week's 22nd International AIDS Conference in Amsterdam with calls to move the next confab out of the San Francisco Bay Area.

A new Spanish-language PrEP campaign has launched to raise awareness about the HIV prevention pill in Latino communities.

The U.S. Food and Drug Administration this week approved Truvada PrEP for adolescents, making the once-daily HIV prevention pill more widely available to a group with a disproportionately high risk of infection.

African-American and Latino men continue to have a disproportionately high likelihood of new HIV infections, according to the latest HIV surveillance data from the Centers for Disease Control and Prevention.

The International AIDS Society's decision to hold its next large conference in San Francisco and Oakland in July 2020 has provoked controversy at both the local and global levels.

Before there was Getting to Zero, which aims to dramatically reduce HIV transmission, HIV-related deaths, and stigma by 2020, San Francisco joined Fast-Track Cities, which attempts to do the same thing in cities around the world.

While PrEP usage has reached more than 75,000 people in the U.S., attendees at an annual conference were told the HIV prevention medication is still not reaching those who could benefit from it, including minority men who have sex with men.

The San Francisco Department of Public Health has launched a new campaign to increase PrEP use among African-Americans, in an effort to help end disparities in new HIV infections, especially among black gay and bi men.

The U.S. Food and Drug Administration last week approved Biktarvy, a one-pill, once-daily combination that contains a new HIV integrase inhibitor and a kidney- and bone-friendly version of tenofovir.